Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsNA

Feasibility of Ambulatory Talc. Pleurodesis

Sponsor: David Rollins

NCT ID: NCT06682936

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
ambulatory chest drain and talc pleurodesis (procedure)
How long the study runs
Study runs about 13 months (dates as stated)
About the drug or intervention
ambulatory chest drain and talc pleurodesis — procedure: a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
18 Years and over
Who
All
Number of participants
15
Started
2024-01-10
Last checked
2024-11

Plain English Summary

What is this study?

  • • Testing a new treatment for malignant pleural effusion
  • • NA - 15 participants
  • • Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with malignant pleural effusion

Where?

  • • Stockton-on-Tees - North Tees and Hartlepool NHS foundation trust

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life. The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.

More detail

Eligible patients will be offered enrolment in the trial along with standard of care options. Participants who agree to take part in the trial would be consented for chest drain, talc pleurodesis on an ambulatory pathway. On day 1 a standard chest drain would be inserted in the morning and large volume fluid removal would commence using an underwater seal bottle- as per standard care. A chest x-ray would be undertaken to confirm drain position, as per standard care. The investigators would remove 1000mls of fluid (stopping earlier if not tolerated) and the clamp the drain for one hour. The investigators would then open the drain again and drain up to 500mls before again clamping for one hour. The investigators would repeat this process as frequently as possible until the end of the working day. The drain would then be connected to an ambulatory bag instead of the underwater seal bottle and left in the open position. The patient would then be sent home to return on day 2. On day 2 the drain would be flushed, aspirated and the output assessed. If there is still fluid output the investigators would drain up to 500mls and close the drain for an hour and repeat. If there is no further output the investigators would undertake a chest x ray to ensure the effusion has resolved and the lung has fully inflated. If it has the investigators would proceed to talc slurry instillation (with 20mls 1% lidocaine as per standard practice) and clamp the drain for 2 hours. After this the investigators would open the drain again and drain up to 500mls and close the drain for an hour. The investigators would repeat this as required and again the patient would return home with an ambulatory bag left open. If the effusion has resolved but the lung has not fully expanded due to underlying disease then the investigators would simply remove the chest drain as pleurodesis will not be possible. On day 3 the drain would be flushed, aspirated and the output assessed. If there is still fluid output the investigators would drain up to 500mls and close the drain for an hour and repeat. If there is no further output the investigators would undertake a chest x ray to ensure the effusion has resolved and the lung has fully inflated. the investigators would then remove the drain and repeat the x-ray to confirm there have been no complications. the investigators would then consider the intervention complete and revert to standard care (open access follow up ) If there was still significant fluid output the investigators would repeatedly drain 500ml volumes of fluid and clamp the drain for an hour after each 500ml until dry. The investigators would ask patients to complete a very brief questionnaire (visual analogue scale) on breathlessness and chest pain on day 1 - before intervention, 1 hour post drain insertion, at the end of the day and on day 2 and 3 on first encounter and at the end of the day. The investigators would also repeat the questionnaire on day 30 along with their satisfaction with the procedure and if participants would have preferred to have stayed in hospital for the procedure (and why)

Malignant Pleural EffusionMalignancyPalliative Care

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

What the study is looking for

  • ✓Malignant pleural effusion
  • ✓Life expectancy \>30 days
  • ✓WHO PS 1-2 (3 if due to dyspnoea)

Who cannot take part

  • ✗Previous failed pleurodesis (on affected side)
  • ✗Known non-expansile lung
See the full criteria
Inclusion Criteria: * Malignant pleural effusion * Life expectancy \>30 days * WHO PS 1-2 (3 if due to dyspnoea) Exclusion Criteria: * Previous failed pleurodesis (on affected side) * Known non-expansile lung

Where Is This Study? (1 UK site)

North Tees and Hartlepool NHS foundation trust

Stockton-on-Tees TS19 8PE, United Kingdom

Recruiting
Site contact (verified)
Kevin Conroy, MBBS, FRCP01642624615kevin.conroy@nhs.net

How to Get in Touch

Kevin Conroy, MBBS, FRCP

Sponsor contact

CONTACT

01642624615 kevin.conroy@nhs.net
Data sourced from ClinicalTrials.gov · Last verified: 2024-11